SSA
SLN

Schonfeld Strategic Advisors’s Silence Therapeutics SLN Stock Holding History

Schonfeld Strategic Advisors’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-149,996
Closed -$423K – 2496
2025
Q1 		$423K Buy
149,996
+26,796
+22% +$131K ﹤0.01% 1651
2024
Q4 		$848K Sell
123,200
-42,800
-26% -$552K ﹤0.01% 1186
2024
Q3 		$3.02M Buy
166,000
+90,963
+121% +$1.69M 0.02% 722
2024
Q2 		$1.43M Sell
75,037
-57,963
-44% -$1.23M 0.01% 1052
2024
Q1 		$2.87M Buy
133,000
+83,800
+170% +$1.82M 0.02% 858
2023
Q4 		$855K Buy
49,200
+2,800
+6% +$31.4K 0.01% 1089
2023
Q3 		$456K Sell
46,400
-600
-1% -$4.43K ﹤0.01% 1230
2023
Q2 		$259K Buy
47,000
+5,900
+14% +$35.6K ﹤0.01% 1448
2023
Q1 		$255K Buy
41,100
+11,600
+39% +$137K ﹤0.01% 1446
2022
Q4 		$450K Buy
+29,500
New +$387K ﹤0.01% 1588

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Schonfeld Strategic Advisors's SLN Position: Q2 2025 in Review

Schonfeld Strategic Advisors sold out of Silence Therapeutics (SLN) in Q2 2025, closing a stake of 149,996 shares — an estimated $423K sold.

Schonfeld Strategic Advisors first reported a position in SLN in Q4 2022 and held it in 10 quarters. The position peaked at $3.02M in Q3 2024. 55 funds tracked by Wall St. Rank hold SLN as of Q2 2025.

  • Schonfeld Strategic Advisors reported no remaining Silence Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 149,996 Silence Therapeutics shares in Q2 2025, an estimated $423K.
  • Schonfeld Strategic Advisors first reported a position in Silence Therapeutics in Q4 2022 and held it in 10 quarters.
  • Schonfeld Strategic Advisors's Silence Therapeutics position peaked at $3.02M in Q3 2024.
  • 55 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.